25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Poolbeg Pharma PLC
Buy, Hold or Sell?

Let's analyze Poolbeg Pharma PLC together

I guess you are interested in Poolbeg Pharma PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Poolbeg Pharma PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Poolbeg Pharma PLC

I send you an email if I find something interesting about Poolbeg Pharma PLC.

1. Quick Overview

1.1. Quick analysis of Poolbeg Pharma PLC (30 sec.)










1.2. What can you expect buying and holding a share of Poolbeg Pharma PLC? (30 sec.)

How much money do you get?

How much money do you get?
p0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
p2.89
Expected worth in 1 year
p-0.22
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
p-3.10
Return On Investment
-60.9%

For what price can you sell your share?

Current Price per Share
p5.10
Expected price per share
p3.551 - p6.96
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Poolbeg Pharma PLC (5 min.)




Live pricePrice per Share (EOD)
p5.10

2.2. Growth of Poolbeg Pharma PLC (5 min.)




Is Poolbeg Pharma PLC growing?

Current yearPrevious yearGrowGrow %
How rich?$17.9m$22.7m-$4.8m-26.9%

How much money is Poolbeg Pharma PLC making?

Current yearPrevious yearGrowGrow %
Making money-$4.8m-$5.8m$936.1k19.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Poolbeg Pharma PLC (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Poolbeg Pharma PLC?

Welcome investor! Poolbeg Pharma PLC's management wants to use your money to grow the business. In return you get a share of Poolbeg Pharma PLC.

First you should know what it really means to hold a share of Poolbeg Pharma PLC. And how you can make/lose money.

Speculation

The Price per Share of Poolbeg Pharma PLC is p5.1. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Poolbeg Pharma PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Poolbeg Pharma PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is p2.89. Based on the TTM, the Book Value Change Per Share is p-0.78 per quarter. Based on the YOY, the Book Value Change Per Share is p-0.85 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is p0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Poolbeg Pharma PLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 p% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Share
Usd Eps-0.01-0.2%-0.01-0.2%-0.01-0.2%-0.01-0.2%-0.01-0.2%
Usd Book Value Change Per Share-0.01-0.2%-0.01-0.2%-0.01-0.2%0.010.2%0.010.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.2%-0.01-0.2%-0.01-0.2%0.010.2%0.010.2%
Usd Price Per Share0.11-0.11-0.08-0.10-0.10-
Price to Earnings Ratio-11.51--11.51--6.46--11.07--11.07-
Price-to-Total Gains Ratio-11.66--11.66--7.11--5.55--5.55-
Price to Book Ratio3.13-3.13-1.65-2.30-2.30-
Price-to-Total Gains Ratio-11.66--11.66--7.11--5.55--5.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0632349
Number of shares15814
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.01
Usd Total Gains Per Share-0.010.01
Gains per Quarter (15814 shares)-152.20188.78
Gains per Year (15814 shares)-608.78755.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-609-6190755745
20-1218-1228015101500
30-1826-1837022652255
40-2435-2446030213010
50-3044-3055037763765
60-3653-3664045314520
70-4261-4273052865275
80-4870-4882060416030
90-5479-5491067966785
100-6088-6100075517540

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.03.00.00.0%0.03.00.00.0%0.03.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.02.00.033.3%1.02.00.033.3%1.02.00.033.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.03.00.0%0.00.03.00.0%0.00.03.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.02.00.033.3%1.02.00.033.3%1.02.00.033.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Poolbeg Pharma PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.776-0.7760%-0.851+10%0.963-181%0.963-181%
Book Value Per Share--2.8882.8880%3.665-21%3.690-22%3.690-22%
Current Ratio--13.69013.6900%17.759-23%26.811-49%26.811-49%
Debt To Asset Ratio--0.0640.0640%0.050+28%0.044+44%0.044+44%
Debt To Equity Ratio--0.0680.0680%0.053+29%0.047+46%0.047+46%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--5643500000.0005643500000.0000%4547700000.000+24%5664100000.0000%5664100000.0000%
Eps---0.786-0.7860%-0.937+19%-0.782-1%-0.782-1%
Ev To Ebitda Ratio---12.111-12.1110%-9.169-24%-16.873+39%-16.873+39%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.804-0.8040%-0.993+23%-0.748-7%-0.748-7%
Free Cash Flow To Equity Per Share---0.804-0.8040%-0.993+23%0.797-201%0.797-201%
Gross Profit Margin--1.8511.8510%1.000+85%1.284+44%1.284+44%
Market Cap2550000000.000-77%4525000000.0004525000000.0000%3025000000.000+50%4100000000.000+10%4100000000.000+10%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.766-77%3.1333.1330%1.651+90%2.296+36%2.296+36%
Pe Ratio-6.487+44%-11.511-11.5110%-6.455-44%-11.072-4%-11.072-4%
Price Per Share5.100-77%9.0509.0500%6.050+50%8.200+10%8.200+10%
Price To Free Cash Flow Ratio-6.340+44%-11.251-11.2510%-6.093-46%-12.891+15%-12.891+15%
Price To Total Gains Ratio-6.570+44%-11.659-11.6590%-7.106-39%-5.554-52%-5.554-52%
Quick Ratio--13.69013.6900%17.759-23%26.811-49%26.811-49%
Return On Assets---0.255-0.2550%-0.243-5%-0.200-22%-0.200-22%
Return On Equity---0.272-0.2720%-0.256-6%-0.210-23%-0.210-23%
Total Gains Per Share---0.776-0.7760%-0.851+10%0.963-181%0.963-181%
Usd Book Value--17906635.80017906635.8000%22718687.700-21%22874088.500-22%22874088.500-22%
Usd Book Value Change Per Share---0.010-0.0100%-0.011+10%0.012-181%0.012-181%
Usd Book Value Per Share--0.0360.0360%0.045-21%0.046-22%0.046-22%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--69973756.50069973756.5000%56386932.300+24%70229175.9000%70229175.9000%
Usd Eps---0.010-0.0100%-0.012+19%-0.010-1%-0.010-1%
Usd Free Cash Flow---4986877.800-4986877.8000%-6156103.500+23%-4634746.200-7%-4634746.200-7%
Usd Free Cash Flow Per Share---0.010-0.0100%-0.012+23%-0.009-7%-0.009-7%
Usd Free Cash Flow To Equity Per Share---0.010-0.0100%-0.012+23%0.010-201%0.010-201%
Usd Market Cap31617450.000-77%56105475.00056105475.0000%37506975.000+50%50835900.000+10%50835900.000+10%
Usd Price Per Share0.063-77%0.1120.1120%0.075+50%0.102+10%0.102+10%
Usd Profit---4874046.900-4874046.9000%-5810171.400+19%-4526874.900-7%-4526874.900-7%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.010-0.0100%-0.011+10%0.012-181%0.012-181%
 EOD+3 -5MRQTTM+0 -0YOY+20 -135Y+6 -2710Y+6 -27

3.3 Fundamental Score

Let's check the fundamental score of Poolbeg Pharma PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.487
Price to Book Ratio (EOD)Between0-11.766
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than113.690
Current Ratio (MRQ)Greater than113.690
Debt to Asset Ratio (MRQ)Less than10.064
Debt to Equity Ratio (MRQ)Less than10.068
Return on Equity (MRQ)Greater than0.15-0.272
Return on Assets (MRQ)Greater than0.05-0.255
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Poolbeg Pharma PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose5.100
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Poolbeg Pharma PLC

Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut. Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Fundamental data was last updated by Penke on 2025-01-29 16:08:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Poolbeg Pharma PLC earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Poolbeg Pharma PLC to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that 0.00 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Poolbeg Pharma PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--101.2%+101.2%
TTM--211.2%+211.2%
YOY--208.6%+208.6%
5Y--342.2%+342.2%
10Y--487.5%+487.5%
4.3.1.2. Return on Assets

Shows how efficient Poolbeg Pharma PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Poolbeg Pharma PLC to the Biotechnology industry mean.
  • -25.5% Return on Assets means that Poolbeg Pharma PLC generated -0.25 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Poolbeg Pharma PLC:

  • The MRQ is -25.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -25.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.5%TTM-25.5%0.0%
TTM-25.5%YOY-24.3%-1.2%
TTM-25.5%5Y-20.0%-5.5%
5Y-20.0%10Y-20.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.5%-12.4%-13.1%
TTM-25.5%-12.4%-13.1%
YOY-24.3%-11.9%-12.4%
5Y-20.0%-13.2%-6.8%
10Y-20.0%-15.3%-4.7%
4.3.1.3. Return on Equity

Shows how efficient Poolbeg Pharma PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Poolbeg Pharma PLC to the Biotechnology industry mean.
  • -27.2% Return on Equity means Poolbeg Pharma PLC generated -0.27 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Poolbeg Pharma PLC:

  • The MRQ is -27.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -27.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.2%TTM-27.2%0.0%
TTM-27.2%YOY-25.6%-1.6%
TTM-27.2%5Y-21.0%-6.2%
5Y-21.0%10Y-21.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.2%-15.9%-11.3%
TTM-27.2%-17.1%-10.1%
YOY-25.6%-15.4%-10.2%
5Y-21.0%-19.5%-1.5%
10Y-21.0%-20.6%-0.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Poolbeg Pharma PLC.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Poolbeg Pharma PLC is operating .

  • Measures how much profit Poolbeg Pharma PLC makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Poolbeg Pharma PLC to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Poolbeg Pharma PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--201.5%+201.5%
TTM--316.3%+316.3%
YOY--217.2%+217.2%
5Y--368.2%+368.2%
10Y--486.9%+486.9%
4.3.2.2. Operating Ratio

Measures how efficient Poolbeg Pharma PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are 0.00 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Poolbeg Pharma PLC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.160-2.160
TTM-3.220-3.220
YOY-3.231-3.231
5Y-4.740-4.740
10Y-6.437-6.437
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Poolbeg Pharma PLC.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Poolbeg Pharma PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.69 means the company has 13.69 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Poolbeg Pharma PLC:

  • The MRQ is 13.690. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.690. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.690TTM13.6900.000
TTM13.690YOY17.759-4.069
TTM13.6905Y26.811-13.121
5Y26.81110Y26.8110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.6903.608+10.082
TTM13.6903.862+9.828
YOY17.7594.596+13.163
5Y26.8115.968+20.843
10Y26.8116.183+20.628
4.4.3.2. Quick Ratio

Measures if Poolbeg Pharma PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Poolbeg Pharma PLC to the Biotechnology industry mean.
  • A Quick Ratio of 13.69 means the company can pay off 13.69 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Poolbeg Pharma PLC:

  • The MRQ is 13.690. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 13.690. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ13.690TTM13.6900.000
TTM13.690YOY17.759-4.069
TTM13.6905Y26.811-13.121
5Y26.81110Y26.8110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.6903.010+10.680
TTM13.6903.351+10.339
YOY17.7594.345+13.414
5Y26.8115.954+20.857
10Y26.8116.490+20.321
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Poolbeg Pharma PLC.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Poolbeg Pharma PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Poolbeg Pharma PLC to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that Poolbeg Pharma PLC assets are financed with 6.4% credit (debt) and the remaining percentage (100% - 6.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Poolbeg Pharma PLC:

  • The MRQ is 0.064. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.064. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.064TTM0.0640.000
TTM0.064YOY0.050+0.014
TTM0.0645Y0.044+0.020
5Y0.04410Y0.0440.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0640.340-0.276
TTM0.0640.342-0.278
YOY0.0500.316-0.266
5Y0.0440.364-0.320
10Y0.0440.384-0.340
4.5.4.2. Debt to Equity Ratio

Measures if Poolbeg Pharma PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Poolbeg Pharma PLC to the Biotechnology industry mean.
  • A Debt to Equity ratio of 6.8% means that company has 0.07 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Poolbeg Pharma PLC:

  • The MRQ is 0.068. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.068. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.068TTM0.0680.000
TTM0.068YOY0.053+0.016
TTM0.0685Y0.047+0.021
5Y0.04710Y0.0470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0680.385-0.317
TTM0.0680.427-0.359
YOY0.0530.391-0.338
5Y0.0470.450-0.403
10Y0.0470.492-0.445
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Poolbeg Pharma PLC generates.

  • Above 15 is considered overpriced but always compare Poolbeg Pharma PLC to the Biotechnology industry mean.
  • A PE ratio of -11.51 means the investor is paying -11.51 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Poolbeg Pharma PLC:

  • The EOD is -6.487. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.511. Based on the earnings, the company is expensive. -2
  • The TTM is -11.511. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.487MRQ-11.511+5.024
MRQ-11.511TTM-11.5110.000
TTM-11.511YOY-6.455-5.056
TTM-11.5115Y-11.072-0.439
5Y-11.07210Y-11.0720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.487-2.264-4.223
MRQ-11.511-2.704-8.807
TTM-11.511-3.241-8.270
YOY-6.455-3.350-3.105
5Y-11.072-6.130-4.942
10Y-11.072-6.726-4.346
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Poolbeg Pharma PLC:

  • The EOD is -6.340. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.251. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.251. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.340MRQ-11.251+4.910
MRQ-11.251TTM-11.2510.000
TTM-11.251YOY-6.093-5.158
TTM-11.2515Y-12.891+1.640
5Y-12.89110Y-12.8910.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.340-3.079-3.261
MRQ-11.251-3.598-7.653
TTM-11.251-3.829-7.422
YOY-6.093-4.518-1.575
5Y-12.891-8.235-4.656
10Y-12.891-9.265-3.626
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Poolbeg Pharma PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.13 means the investor is paying 3.13 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of Poolbeg Pharma PLC:

  • The EOD is 1.766. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.133. Based on the equity, the company is fair priced.
  • The TTM is 3.133. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.766MRQ3.133-1.368
MRQ3.133TTM3.1330.000
TTM3.133YOY1.651+1.482
TTM3.1335Y2.296+0.837
5Y2.29610Y2.2960.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.7661.930-0.164
MRQ3.1332.239+0.894
TTM3.1332.443+0.690
YOY1.6512.459-0.808
5Y2.2963.744-1.448
10Y2.2964.444-2.148
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in GBP. All numbers in thousands.

Summary
Total Assets15,428
Total Liabilities986
Total Stockholder Equity14,442
 As reported
Total Liabilities 986
Total Stockholder Equity+ 14,442
Total Assets = 15,428

Assets

Total Assets15,428
Total Current Assets13,498
Long-term Assets1,930
Total Current Assets
Cash And Cash Equivalents 12,171
Net Receivables 1,327
Inventory -1,327
Other Current Assets 1,327
Total Current Assets  (as reported)13,498
Total Current Assets  (calculated)13,498
+/-0
Long-term Assets
Intangible Assets 1,930
Long-term Assets  (as reported)1,930
Long-term Assets  (calculated)1,930
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities986
Long-term Liabilities0
Total Stockholder Equity14,442
Total Current Liabilities
Accounts payable 79
Other Current Liabilities 855
Total Current Liabilities  (as reported)986
Total Current Liabilities  (calculated)934
+/- 52
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock100
Retained Earnings -10,953
Accumulated Other Comprehensive Income 740
Other Stockholders Equity 24,555
Total Stockholder Equity (as reported)14,442
Total Stockholder Equity (calculated)14,442
+/-0
Other
Capital Stock100
Cash and Short Term Investments 12,171
Common Stock Shares Outstanding 500
Liabilities and Stockholders Equity 15,428
Net Debt -12,171
Net Invested Capital 14,442
Net Working Capital 12,512



6.2. Balance Sheets Structured

Currency in GBP. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-31
> Total Assets 
23,018
19,289
15,428
15,42819,28923,018
   > Total Current Assets 
21,455
17,155
13,498
13,49817,15521,455
       Cash And Cash Equivalents 
20,949
16,193
12,171
12,17116,19320,949
       Net Receivables 
506
962
1,327
1,327962506
   > Long-term Assets 
1,563
2,134
1,930
1,9302,1341,563
       Intangible Assets 
1,563
2,134
1,930
1,9302,1341,563
> Total Liabilities 
438
966
986
986966438
   > Total Current Liabilities 
438
966
986
986966438
       Accounts payable 
79
293
79
7929379
       Other Current Liabilities 
312
627
855
855627312
   > Long-term Liabilities 000
> Total Stockholder Equity
22,580
18,323
14,442
14,44218,32322,580
   Common Stock
100
100
100
100100100
   Retained Earnings Total Equity000
   Accumulated Other Comprehensive Income 
-620
-4,877
740
740-4,877-620
   Capital Surplus 000
   Treasury Stock000
   Other Stockholders Equity 
22,480
18,223
24,555
24,55518,22322,480



6.3. Balance Sheets

Currency in GBP. All numbers in thousands.




6.4. Cash Flows

Currency in GBP. All numbers in thousands.




6.5. Income Statements

Currency in GBP. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in GBP. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-26
Gross Profit-26-26
 
Operating Income (+$)
Gross Profit-26
Operating Expense-5,039
Operating Income-5,039-5,065
 
Operating Expense (+$)
Research Development1,677
Selling General Administrative3,376
Selling And Marketing Expenses3,347
Operating Expense5,0398,400
 
Net Interest Income (+$)
Interest Income534
Interest Expense-0
Other Finance Cost-0
Net Interest Income534
 
Pretax Income (+$)
Operating Income-5,039
Net Interest Income534
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-4,505-5,573
EBIT - interestExpense = -4,686
-4,505
-3,931
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-4,686-4,505
Earnings Before Interest and Taxes (EBITDA)-4,660
 
After tax Income (+$)
Income Before Tax-4,505
Tax Provision--574
Net Income From Continuing Ops-3,931-3,931
Net Income-3,931
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses5,039
Total Other Income/Expenses Net534-534
 

Technical Analysis of Poolbeg Pharma PLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Poolbeg Pharma PLC. The general trend of Poolbeg Pharma PLC is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Poolbeg Pharma PLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Poolbeg Pharma PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.8 < 6.38 < 6.96.

The bearish price targets are: 4.4 > 3.551.

Tweet this
Poolbeg Pharma PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Poolbeg Pharma PLC. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Poolbeg Pharma PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily Moving Average Convergence/Divergence (MACD) ChartPoolbeg Pharma PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Poolbeg Pharma PLC. The current adx is .

Poolbeg Pharma PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily Relative Strength Index (RSI) ChartPoolbeg Pharma PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily Stochastic Oscillator ChartPoolbeg Pharma PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily Commodity Channel Index (CCI) ChartPoolbeg Pharma PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily Chande Momentum Oscillator (CMO) ChartPoolbeg Pharma PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily Williams %R ChartPoolbeg Pharma PLC Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily Average True Range (ATR) ChartPoolbeg Pharma PLC Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily On-Balance Volume (OBV) ChartPoolbeg Pharma PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Poolbeg Pharma PLC.

Poolbeg Pharma PLC Daily Money Flow Index (MFI) ChartPoolbeg Pharma PLC Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Poolbeg Pharma PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-09-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-09BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Poolbeg Pharma PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Poolbeg Pharma PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose5.100
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Poolbeg Pharma PLC with someone you think should read this too:
  • Are you bullish or bearish on Poolbeg Pharma PLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Poolbeg Pharma PLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Poolbeg Pharma PLC

I send you an email if I find something interesting about Poolbeg Pharma PLC.


Comments

How you think about this?

Leave a comment

Stay informed about Poolbeg Pharma PLC.

Receive notifications about Poolbeg Pharma PLC in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.